Chronic Lymphocytic Leukemia | Specialty

Current Role for Chemoimmunotherapy in CLL

July 30th 2020

Treating CLL During COVID-19

July 30th 2020

Frontline Treatment Options in CLL

July 30th 2020

Selecting Frontline Therapy for CLL

July 30th 2020

COVID-19 and CLL Treatment Initiation

July 30th 2020

Selecting First-Line Therapy for CLL

July 30th 2020

Advances in Frontline Therapy for CLL

July 30th 2020

Impact of COVID-19 on Management of CLL

July 30th 2020

Initial Work-up for Chronic Lymphocytic Leukemia

July 30th 2020

EU Panel Recommends Ibrutinib/Rituximab Combo for Frontline CLL

July 24th 2020

The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion for ibrutinib in combination with rituximab for use in treatment-naïve patients with chronic lymphocytic leukemia.

Dr. Al-Sawaf on Continual MRD Assessment ​After Venetoclax/Obinutuzumab in CLL

July 20th 2020

Othman Al-Sawaf, MD, discusses ongoing minimal residual disease assessment for patients in the phase 3 CLL14 study with chronic lymphocytic leukemia.

Dr. Davids on the Design of the Phase 3 UNITY Trials in Relapsed/Refractory CLL and MCL

July 17th 2020

Matthew S. Davids, MD, MMSc, discusses the design of the UNITY trials in patients with relapsed/refractory chronic lymphocytic leukemia and mantle cell lymphoma.

Ongoing Trial Evaluates Zanubrutinib in BTK-Intolerant B-Cell Malignancies

July 17th 2020

Ian W. Flinn, MD, PhD, discusses the adverse effects associated with BTK inhibitors in B-cell malignancies, as well as the design of an ongoing phase 2 study with zanubrutinib.

Al-Sawaf Highlights the Benefit of Fixed-Duration Venetoclax/Obinutuzumab in CLL

July 17th 2020

Othman Al-Sawaf, MD, discusses the data from the CLL14 trial with obinutuzumab/venetoclax and the benefits of a fixed-dose treatment in select patients with chronic lymphocytic leukemia.

Expert Confirms Efficacy, Safety in Final ASCEND Data With Acalabrutinib in Relapsed/Refractory CLL

July 17th 2020

Paolo Ghia, MD, PhD, discusses the final results from the phase 3 ASCEND trial with acalabrutinib monotherapy in patients with relapsed/refractory CLL.

Dr. Ghia on the Shift From Chemotherapy to Novel Agents in CLL

July 15th 2020

Paolo Ghia, MD, PhD, discusses how use the of chemotherapy is decreasing in favor of novel agents in chronic lymphocytic leukemia.

Dr. Ghia on Efficacy and Safety of Acalabrutinib in Relapsed/Refractory CLL

July 9th 2020

Paolo Ghia, MD, PhD, discusses the efficacy and safety of acalabrutinib in the phase 3 ASCEND trial in relapsed/refractory chronic lymphocytic leukemia.

Dr. Davids on Rationale for Ibrutinib/Umbralisib Combo in R/R CLL and MCL

July 6th 2020

Matthew S. Davids, MD, MMSc, discusses the rationale for examining ibrutinib in combination with umbralisib in relapsed/refractory chronic lymphocytic leukemia or mantle cell lymphoma.

Dr. Al-Sawaf on Fixed-Duration Versus Continuous Treatment in CLL

July 1st 2020

Othman Al-Sawaf, MD, discusses benefits of a fixed duration treatment versus continuous treatment in chronic lymphocytic leukemia.

Leonard Leads Discussion on Latest Developments in Leukemias and Lymphomas

June 26th 2020

Data in Richter’s transformation, Hodgkin lymphoma, Waldenström macroglobulinemia, and indolent lymphoma were presented at the 2020 ASCO Virtual Scientific Program, and although not entirely practice changing, are deserving of attention.